{"entity":{"id":"triptorelin","kind":"drug","name":"Triptorelin","aka":["Decapeptyl","Triptodur (paediatric)"],"tldr":"Triptorelin (Trelstar) is a one-, three- or six-monthly injection that switches off testosterone production for men with advanced prostate cancer.","summary":"Triptorelin pamoate was approved by the FDA in June 2000 (3.75 mg monthly), with 11.25 mg three-monthly (2001) and 22.5 mg six-monthly (2010) depots following, for palliative treatment of advanced prostate cancer; the pivotal randomised trial of 277 men showed castrate testosterone suppression comparable to leuprolide. As Decapeptyl it has been used in Europe since the 1980s for prostate cancer, endometriosis and, in premenopausal breast cancer, for ovarian function suppression in the SOFT and TEXT trials that established the combination with exemestane. Hot flushes, loss of bone density, metabolic effects and initial flare (covered with an antiandrogen) are shared with the class.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Triptorelin","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=triptorelin"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/triptorelin-pamoate"}],"tags":["nci-list"],"related":["leuprolide","goserelin"],"cancers":["prostate","breast-hr-positive"],"sections":[],"technologies":["androgen-deprivation","endocrine-therapy"],"targets":["androgen-receptor"],"drugs":[],"companies":["verity-pharma","ipsen"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00066703","nct01020448","nct00412022"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Trelstar","modality":"GnRH agonist depot","mechanism":"Synthetic decapeptide GnRH agonist; continuous stimulation desensitises pituitary GnRH receptors, suppressing LH and testosterone to castrate levels after an initial surge.","approvals":[{"region":"US","year":2000,"indication":"Palliative treatment of advanced prostate cancer"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/triptorelin/","neighbours":{"drug":[{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/"},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/"},{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"company":[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/"},{"id":"verity-pharma","kind":"company","name":"Verity Pharmaceuticals","route":"/companies/verity-pharma/"}],"trial":[{"id":"nct07455903","kind":"trial","name":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","route":"/trials/nct07455903/"},{"id":"nct01020448","kind":"trial","name":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","route":"/trials/nct01020448/"},{"id":"getug-afu-17","kind":"trial","name":"GETUG-AFU 17","route":"/trials/getug-afu-17/"},{"id":"nct00412022","kind":"trial","name":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer","route":"/trials/nct00412022/"},{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/"},{"id":"nct00936390","kind":"trial","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00936390/"},{"id":"nct03678025","kind":"trial","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","route":"/trials/nct03678025/"},{"id":"nct04423211","kind":"trial","name":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","route":"/trials/nct04423211/"},{"id":"nct00066703","kind":"trial","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","route":"/trials/nct00066703/"},{"id":"nct00104741","kind":"trial","name":"Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","route":"/trials/nct00104741/"},{"id":"nct04513717","kind":"trial","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","route":"/trials/nct04513717/"}]}}